Singapore also secured six major biologics investments over the last few years totaling about S$2.5 billion from Roche, Lonza, GlaxoSmithKline, Novartis and Baxter, which could potentially create about 1,300 new jobs” (MOH, 2009).
What exactly is biologics?
Biologics is a subset of manufacturing processes which also comprises of pharmaceuticals and nutritionals. They are medicinal products manufactured from [...]

Within a short span of 2 years, 4 major biomedical companies announced their commercial-scale biologics manufacturing investments in Singapore. These investments include, GlaxoSmithKline’s Biologics’ vaccine plant, Lonza’s two mammalian cell culture facilities, Novartis cell culture plant and Genentech microbial facility.
So what made these companies come to Singapore?
Firstly, it was due to the country’s heavy investments [...]

A*STAR’s Bioprocessing Technology Institute (BTI) and GSK Biologicals SA Belgium have recently sealed an agreement to collaborate in three vaccine and adjuvant system related research projects. This partnership aims to bring new approaches to vaccine development and production.
With biologics becoming increasingly profitable with growth in sales doubling that of traditional pharmaceuticals, BTI’s work on characterizing [...]

A key component of Singapore’s manufacturing sector is Pharmaceutical Manufacturing, as many pharmaceutical companies such as GlaxoSmithKline, Merck, Pfizer and Schering-Plough set-up facilities here. These are the rewards of the Singapore government’s 17 years of hard work to attract such big names to Singapore.

In recent years, the manufacturing of drugs has shifted from using the [...]